Physician profile
Mark Delman
NPI 1932345931
$739.34
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $459 · 2020: $198 · 2022: $82.38.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $157.50 | 2019-2020 | |
| Gilead Sciences, INC. | $134.16 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $106.22 | 2019-2020 | |
| Viiv Healthcare Company | $97.73 | 2020-2022 | |
| Allergan, INC. | $50.29 | 2019-2020 | |
| Melinta Therapeutics, LLC | $39.99 | 2019 | |
| Abbvie INC. | $31.07 | 2019 | |
| Paratek Pharmaceuticals, INC. | $21.89 | 2020 | |
| Nabriva Therapeutics, Plc | $21.68 | 2020 | |
| Tetraphase Pharmaceuticals, INC. | $17.92 | 2019 | |
| Insmed, INC. | $17.31 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.57 | 2022 | |
| Philips North America LLC | $14.54 | 2019 | |
| Pfizer INC. | $13.47 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Delman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.